Low rectal cancer accounts for a high proportion of colorectal cancer cases in China, and the choice of treatment strategies critically impacts patient prognosis and quality of life. With the advancement of precision treatment, clinical decision-making requires integrating multi-dimensional factors to move beyond the traditional "one-size-fits-all" approach. The authors focus on the anatomical complexity, high recurrence risk, and functional preservation demands of low rectal cancer, incorporating the latest research advances to explore precision treatment pathways in terms of preoperative high-resolution magnetic resonance imaging assessment, breakthroughs in immunotherapy and precision surgical techniques. Future efforts should further optimize individua-lized strategies through multimodal assessment and multidisciplinary collaboration, refining inte-grated approaches based on evidence-based medicine to enhance clinical efficacy and patient survival outcomes.

Objective:To design and develop a battlefield first-aid simulated training system, to evaluate the application effect of the system through a quasi-experimental controlled trial, and to provide training means to support the enhancement of Chinese army's first-line treatment capability.Methods:A battlefield first-aid simulated training system was designed and developed with the guidance of the theory of "experiential learning cycle". From March to June 2023, 108 health sergeants who participated in non-academic education training from a military medical university were recruited to a quasi-experimental controlled trial and randomly divided into a control group and an experimental group, with 54 sergeants each. The control group was trained using traditional face-to-face simulation training, and the experimental group was trained using the Battlefield First-aid Simulated Training System. The differences in effects of computer simulation training and traditional face-to-face simulation training were compared, with the primary evaluation indices being the first-aid knowledge level and inferential capability of rescue on the battlefield, and the secondary evaluation indices being the self-perception and training satisfaction. The SPSS 26.0 software was used for conducting the t test, chi-square test or Fisher's exact probability test, and non-parametric test. Results:All 108 subjects completed the training and had an improvement in the knowledge level, self-perception, and inferential capability of rescue after the training ( P<0.001). The difference in the degree of improvement in the knowledge level [(19.93±8.98) vs. (16.55±10.10)] and self-perception [10.50 (7.00, 13.25) vs. 10.00 (7.00, 12.50)] was not statistically significant between the experimental group and the control group ( P>0.05), but the degree of improvement in the inferential capability of rescue of the experimental group [6.00 (5.00, 9.25)] was significantly lower than that of the control group [8.00 (7.00, 11.00)] ( P<0.05). There was no significant difference in the training satisfaction scores between the two groups ( P>0.05). Conclusions:The system has a similar training effect to traditional face-to-face simulation training, but shows a slight deficiency in the improvement in the inferential capability of rescue. It serves as a recommended training resource and format from battlefield first-aid theory learning to practical application. The system still needs to be optimized and improved in the aspects of functionality, simulation, and intellectualization in the future.

Objective:To design and develop a battlefield first-aid simulated training system, to evaluate the application effect of the system through a quasi-experimental controlled trial, and to provide training means to support the enhancement of Chinese army's first-line treatment capability.Methods:A battlefield first-aid simulated training system was designed and developed with the guidance of the theory of "experiential learning cycle". From March to June 2023, 108 health sergeants who participated in non-academic education training from a military medical university were recruited to a quasi-experimental controlled trial and randomly divided into a control group and an experimental group, with 54 sergeants each. The control group was trained using traditional face-to-face simulation training, and the experimental group was trained using the Battlefield First-aid Simulated Training System. The differences in effects of computer simulation training and traditional face-to-face simulation training were compared, with the primary evaluation indices being the first-aid knowledge level and inferential capability of rescue on the battlefield, and the secondary evaluation indices being the self-perception and training satisfaction. The SPSS 26.0 software was used for conducting the t test, chi-square test or Fisher's exact probability test, and non-parametric test. Results:All 108 subjects completed the training and had an improvement in the knowledge level, self-perception, and inferential capability of rescue after the training ( P<0.001). The difference in the degree of improvement in the knowledge level [(19.93±8.98) vs. (16.55±10.10)] and self-perception [10.50 (7.00, 13.25) vs. 10.00 (7.00, 12.50)] was not statistically significant between the experimental group and the control group ( P>0.05), but the degree of improvement in the inferential capability of rescue of the experimental group [6.00 (5.00, 9.25)] was significantly lower than that of the control group [8.00 (7.00, 11.00)] ( P<0.05). There was no significant difference in the training satisfaction scores between the two groups ( P>0.05). Conclusions:The system has a similar training effect to traditional face-to-face simulation training, but shows a slight deficiency in the improvement in the inferential capability of rescue. It serves as a recommended training resource and format from battlefield first-aid theory learning to practical application. The system still needs to be optimized and improved in the aspects of functionality, simulation, and intellectualization in the future.

Low rectal cancer accounts for a high proportion of colorectal cancer cases in China, and the choice of treatment strategies critically impacts patient prognosis and quality of life. With the advancement of precision treatment, clinical decision-making requires integrating multi-dimensional factors to move beyond the traditional "one-size-fits-all" approach. The authors focus on the anatomical complexity, high recurrence risk, and functional preservation demands of low rectal cancer, incorporating the latest research advances to explore precision treatment pathways in terms of preoperative high-resolution magnetic resonance imaging assessment, breakthroughs in immunotherapy and precision surgical techniques. Future efforts should further optimize individua-lized strategies through multimodal assessment and multidisciplinary collaboration, refining inte-grated approaches based on evidence-based medicine to enhance clinical efficacy and patient survival outcomes.

Objective To investigate the expression level of HNRNP A1 in colorectal cancer(CRC)and its prognostic implications.Methods We investigated HNRNP A1 expression level in CRC using HPA,TIMER,and GEPIA databases and analyzed its association with Ki-67 and VEGFA expressions.Kaplan-Meier Plotter database was used to analyze the correlation of HNRNP A1 mRNA levels with the survival rates of CRC patients.Pathway enrichment analysis was performed for predicting the biological roles of HNRNP A1 in CRC progression.Immunohistochemistry and Western blotting were used to examine the protein levels of HNRNP A1 in CRC versus adjacent tissues,and TIMER was used for assessing its expression in the infiltrating immune cells.In RKO/Caco2 cells,the effects of lentivirus-mediated knockdown of HNRNP A1 on cell proliferation and migration were observed,and the inhibitory effect of VPC-80051(a HNRNP A1 inhibitor)on cell proliferation was evaluated to assess its potential as a therapeutic agent.Results HNRNP A1 was significantly overexpressed in CRC tissues and correlated with a poor prognosis of the patients.HNRNP A1 expression level was correlated with the infiltrating immune cells in CRC microenvironment and positively correlated with MKI67 and VEGFA expressions in CRC.A high HNRNP A1 expression predicted a in survival and progression-free survival of CRC patients and was involved in multiple biological processes related with CRC progression.In RKO/Caco2 cells,HNRNP A1 knockdown significantly suppressed cell proliferation and migration,and treatment with VPC-80051 also effectively inhibited CRC cell proliferation.Immunohistochemical study demonstrated a close correlation of HNRNP A1 overexpression with tumor stage of CRC.Conclusion HNRNP A1 is overexpressed in CRC tissues to modulate cell proliferation and migration and is correlated with a poorer prognosis.VPC-80051 can effectively inhibit CRC cell proliferation,suggesting the potential of HNRNP A1 as a therapeutic target for CRC.

Objective To investigate the expression level of HNRNP A1 in colorectal cancer(CRC)and its prognostic implications.Methods We investigated HNRNP A1 expression level in CRC using HPA,TIMER,and GEPIA databases and analyzed its association with Ki-67 and VEGFA expressions.Kaplan-Meier Plotter database was used to analyze the correlation of HNRNP A1 mRNA levels with the survival rates of CRC patients.Pathway enrichment analysis was performed for predicting the biological roles of HNRNP A1 in CRC progression.Immunohistochemistry and Western blotting were used to examine the protein levels of HNRNP A1 in CRC versus adjacent tissues,and TIMER was used for assessing its expression in the infiltrating immune cells.In RKO/Caco2 cells,the effects of lentivirus-mediated knockdown of HNRNP A1 on cell proliferation and migration were observed,and the inhibitory effect of VPC-80051(a HNRNP A1 inhibitor)on cell proliferation was evaluated to assess its potential as a therapeutic agent.Results HNRNP A1 was significantly overexpressed in CRC tissues and correlated with a poor prognosis of the patients.HNRNP A1 expression level was correlated with the infiltrating immune cells in CRC microenvironment and positively correlated with MKI67 and VEGFA expressions in CRC.A high HNRNP A1 expression predicted a in survival and progression-free survival of CRC patients and was involved in multiple biological processes related with CRC progression.In RKO/Caco2 cells,HNRNP A1 knockdown significantly suppressed cell proliferation and migration,and treatment with VPC-80051 also effectively inhibited CRC cell proliferation.Immunohistochemical study demonstrated a close correlation of HNRNP A1 overexpression with tumor stage of CRC.Conclusion HNRNP A1 is overexpressed in CRC tissues to modulate cell proliferation and migration and is correlated with a poorer prognosis.VPC-80051 can effectively inhibit CRC cell proliferation,suggesting the potential of HNRNP A1 as a therapeutic target for CRC.

Chimeric antigen receptor T(CAR-T)cell therapy is a new method of immunotherapy for cancer that has achieved remarkable results in treating blood tumors.However,colorectal cancer(CRC),as a solid tumor,has different characteristics from hematological tumors,which impose certain constraints on the selection of its therapeutic targets and the effectiveness of treatment of CAR-T therapy.Therefore,it is necessary to select therapeutic targets with high specificity and effectiveness according to the characteristics of CRC,as well as to break through the constraints such as adverse effects caused by the treatment and the solid tumor microenvironment,to make CAR-T therapy applicable in the treatment of CRC.This article aimed to summarize the strategy of selecting therapeutic targets for CAR-T cell immunotherapy for CRC,analyze the restrictive factors of this therapy in the treatment of CRC,and forecast the prospect of CAR-T cell immunotherapy for CRC.

This study firstly introduced the mechanism, benefits and applications of irreversible electroporation(IRE) for tumor ablation. In addition, this study also introduced the most advanced IRE systems cleared by FDA or CFDA and IRE research equipment. The clinically licensed IRE systems include the Nanoknife 3.0 of Angiodynamics, the Dophi
Electricity ; Electroporation ; Heart Rate ; Humans ; Neoplasms/therapy*

Platinum antitumor drugs are widely used for clinical treatment because of their unique antitumor mechanisms, significant antitumor effects, and broad antitumor spectrum. Yet shortcomings such as toxic side effects, drug resistance and cross-resistance of platinum-based drugs have limited their further application. Platinum-intercalator conjugates possess different antitumor mechanisms from those of classic platinum drugs, and have unique advantages in overcoming the disadvantages of classic platinum antitumor drugs. The platinum-intercalator conjugates can be classified into six categories based on the different DNA-intercalator: platinum-acridine, platinum-quinoline, platinum-indole, platinum-naphthalimides, platinum-anthraquinone and platinum-based antitumor agents containing other types of intercalating groups. This article summarizes the research progress of platinum-based antitumor drugs containing DNA insertion groups in recent years.

Platinum-based anticancer drugs have been becoming one of the most effective drugs for clinical treatment of malignant tumors for its unique mechanism of action and broad range of anticancer spectrum. But, there are still several problems such as side effects, drug resistance/cross resistance and no-specific targeting, becoming obstacles to restrict its expanding of clinical application. In recent years, supramolecular chemistry drug delivery systems have been gradually concerned for their favorable safety and low toxicity. Supramolecular macrocycles-platinum complexes increased the water solubility, stability and safety of traditional platinum drugs, and have become hot focus of developing novel platinum-based anticancer drugs because of its potential targeting of tumor tissues/organs. This article concentrates in the research progress of the new drug delivery system between platinum-based anticancer drugs with three generations of macrocycles: crown ether, cyclodextrin, cucurbituril and calixarene.